TFMG
5 years ago
$KMPH | #KemPharm, Inc 30% Upside
KemPharm, Inc. is a clinical-stage specialty pharmaceutical company, which engages in the discovery and development of proprietary prodrugs. It focuses in the treatment of serious medical conditions such as attention deficit hyperactivity disorder, pain, and other central nervous system disorders through its platform technology known as Ligand Activated Therapy. The company was founded by Christal M. M. Mickle and Travis C. Mickle on October 30, 2006 and is headquartered in Coralville, IA.
whytestocks
5 years ago
News: $KEM KEMET ALERT: Bragar Eagel & Squire, P.C. Investigates Proposed Sale of KEM and Encourages Investors to Contact the Firm
NEW YORK , Nov. 12, 2019 /PRNewswire/ -- Bragar Eagel & Squire, P.C., a nationally recognized stockholder law firm, has launched an investigation into whether the board members of KEMET Corporation (NYSE: KEM) breached their fiduciary duties or violated the federal securities law...
Read the whole news KEM - KEMET ALERT: Bragar Eagel & Squire, P.C. Investigates Proposed Sale of KEM and Encourages Investors to Contact the Firm
whytestocks
6 years ago
News: $KEM KEMET Announces Preliminary First Quarter Results Exceed Guidance
FORT LAUDERDALE, Fla., Aug. 01, 2019 (GLOBE NEWSWIRE) -- KEMET Corporation (“KEMET” or the “Company”) (NYSE: KEM), a leading global supplier of passive electronic components, today reported preliminary results for its first fiscal quarter ended June 30, 2019...
In case you are interested KEMET Announces Preliminary First Quarter Results Exceed Guidance